Cargando…
TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment
INTRODUCTION: The treatment landscape for de novo metastatic hormone sensitive prostate cancer (mHSPC) is rapidly evolving. With an abundance of available treatment strategies, selecting the optimal strategy for an individual patient is becoming increasingly challenging. TripleAiM1 aims to evaluate...
Autores principales: | van Elst, Tessa, van Basten, Jean-Paul A, van den Berg, Pieter L, van den Bergh, Roderick CN, Bloem, Sjaak, van Dodewaard-de Jong, Joyce M, Hendriks, Mathijs P, Klaver, Sjoerd O, Lalmahomed, Zarina, Luijendijk, Daphne, van de Luijtgaarden, Addy CM, Roelofs, Luc AJ, Vis, André N, Vreugdenhil, Gerard, Vrijhof, Eric HJEJ, Wijsman, Bart P, Bloemendal, Haiko J, Mulders, Peter FA, Mehra, Niven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465920/ https://www.ncbi.nlm.nih.gov/pubmed/37643855 http://dx.doi.org/10.1136/bmjopen-2023-072572 |
Ejemplares similares
-
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy
por: van der Doelen, Maarten J., et al.
Publicado: (2022) -
Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023) -
Palmar Fasciitis and Polyarthritis Syndrome: A Rare Paraneoplastic Syndrome in a Patient With Prostate Carcinoma
por: de Boer, Anouk G., et al.
Publicado: (2020) -
Manufacturers’ views on outcome-based agreements
por: Barjestehvan Waalwijk van Doorn-Khosrovani, Sahar, et al.
Publicado: (2021) -
Digital Resilience Biomarkers for Personalized Health Maintenance and Disease Prevention
por: van den Brink, Willem, et al.
Publicado: (2021)